- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06233474
Une étude de phase 1/2a randomisée, en double aveugle, contrôlée par placebo, sur l'allocétra intra-articulaire dans l'arthrose du genou
This is a double blind, randomized,multi-center study to evaluate the safety and efficacy of intra-articular administration of Allocetra compared to placebo in patients with symptomatic knee osteoarthritis.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Knee osteoarthritis is a degenerative disease driven by physical breakdown of the joint cartilage, together with a chronic inflammation within the knee space. Over time, many patients will develop worsening pain in the joint and functional impairment, which may ultimately require knee replacement.
Allocetra is an immunomodulatory cell-based therapy consisting of allogeneic peripheral blood mononuclear cells that have been modified to be engulfed by macrophages and reprogram them into their homeostatic state.
This Phase 1/2a study is comprised of an open-label safety run-in stage to characterize safety and tolerability of repeated injections of Allocetra to a target knee , followed by a double-blind randomized stage to evaluate the safety and efficacy of Allocetra repeated injections to the target knee compared to placebo, in moderate to severe knee osteoarthritis patients. Patients in both stages will be followed for up to a year following last treatment. the last treatment.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
-
Gandrup, Danemark, 9362
- Sanos Clinic Nordjylland
-
Herlev, Danemark, 2730
- Sanos Clinic Herlev
-
Vejle, Danemark, 7100
- Sanos Clinic Syddanmark
-
-
-
-
-
Ashkelon, Israël, 7830604
- Barzilai Medical Center
-
Haifa, Israël, 7651211
- Rambam Medical Center
-
Petah Tikva, Israël, 4937211
- Hasharon Medical Center
-
Ramat Gan, Israël, 5266202
- Sheba Medical Center
-
Rehovot, Israël, 7661041
- Kaplan Medical Center
-
Tel Aviv, Israël, 6423906
- Ichilov - Tel Aviv Sourasky Medical Center
-
-
-
-
-
Chisinau, Moldavie, 2025
- IMSP Institutul de Cardiologie
-
Chisinau, Moldavie, 2025
- Spitalul Clininc Republican "T. Mosneaga"
-
Chisinau, Moldavie, 2068
- IMSP Sptalul Clinic Municipal "Sfanta Treime"
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 45 - 80 years.
- Chronic osteoarthritis of index knee with knee-related joint pain
- Radiographic evidence of knee osteoarthritis of K-L Grade 2 or 3 in the index knee.
- Knee pain assessed daily over a period of 7 days during the screening period and following wash-out of pain medications
- Patients with chronic knee pain for at least 3 months who have failed to respond adequately to conventional therapy.
- Willing to abstain from other intra-articular treatments and adhere to the protocol restrictions for concomitant medications and therapies during the study.
- Women of childbearing potential and all men must agree to use 2 methods of an adequate contraception prior to study entry and for the duration of study participation through 4 weeks following IP administration.
Exclusion Criteria:
- Wheelchair bound.
- Immunosuppressive therapy
- Any known current or prior tumor of the index knee.
- Any known history or current intra-articular or osseous infection of the index knee.
- Any evidence of clinically significant active infection
- Any known history of inflammatory arthropathy or crystal-deposition arthropathy
- Any known severe systemic cartilage and/or bone disorder, such as, but not limited to, chondrodysplasia, osteogenesis imperfecta.
- Body Mass Index (BMI) >40.
- Any major surgical cartilage treatment within 6 months
- Any ligamentous repair or malalignment correction in the index knee within 6 months
- Major injury to the index knee, such as torn ligament or severe sprain within 6 months
- Clinically relevant knee instability of the index knee
- Severe hip osteoarthritis ipsilateral to the index knee.
- Clinically significant widespread pain syndromes, e.g., fibromyalgia, long COVID syndrome.
- Known coagulopathy, or use of anticoagulation medication or antiaggregant medication;.
- certain tumors, severe cardiac, respiratory or hematologic diseases as defined in the protocol
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: Safety run-in phase - Allocetra increasing dose
An open-label dose escalation phase to characterize the safety and tolerability of Allocetra injections to the knee in different doses and select the Allocetra dose and regimen for the randomized phase. |
Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state |
|
Comparateur placebo: Randomization phase - Placebo.
Three intra-articular injections of placebo into the index knee. |
The control used in this study will be placebo. Placebo solution containing all excipients except for the Allocetra cells. |
|
Expérimental: Randomization phase - Allocetra
Three intra-articular injections of Allocetra at a selected dose, into the index knee. |
Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Treatment-emergent adverse events and Serious adverse events following Allocetra-OTS injection
Délai: 7 months following Day 0
|
Number and severity of adverse events (AEs), serious adverse events (SAEs) and treatment disruptions/ discontinuations throughout the study from Day 0 and up to 6 months following the last injection |
7 months following Day 0
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Weekly average of knee pain.
Délai: 4 months and 7 months following Day 0.
|
Evaluation of change from baseline in weekly average of knee pain as measured using NRS (Numeric Rating Scale ) assessed at 3 months and 6 months from last study treatment. Scores range from 0-10 points, with higher scores indicating greater pain intensity |
4 months and 7 months following Day 0.
|
|
Change from baseline in WOMAC total score.
Délai: 4 months, 7 months and 13 months following Day 0.
|
Change from baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) total score at 3 months, 6 months, and 12 months from last study treatment administration. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations. |
4 months, 7 months and 13 months following Day 0.
|
|
Change in quality of life- Euro Quality of Life-5-dimension (EQ-5D) questionnaire
Délai: 4 months, 7 months and 13 months following Day 0.
|
Change from baseline in QoL as measured by Euro Quality of Life-5-dimension (EQ-5D) questionnaire at 6 months and at 12 months from last study treatment administration. |
4 months, 7 months and 13 months following Day 0.
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Directeur d'études: Lital Weinfeld-Bergman, Senior Director of Clinical Operations
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ENX-CL-05-001
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .